CRSPR at SupportWeekly Chart of CRISPR.
At a support( demand zone).
As soon as it takes of 138 stock will come under bullish territory.
Long CRSPR.
Remember Weekly Charts are used for Investmet Duration greater than 3 months.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.374 CHF
−129.33 M CHF
312.53 M CHF
81.67 M
About CRISPR Therapeutics AG
Sector
Industry
CEO
Samarth Kulkarni
Website
Headquarters
Zug
Founded
2013
ISIN
CH0334081137
FIGI
BBG00LVD6DC2
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 1CG is 45.169 CHF — it has increased by 2.32% in the past 24 hours. Watch CRISPR THERAPEUTIC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CRISPR THERAPEUTIC stocks are traded under the ticker 1CG.
1CG stock has risen by 7.95% compared to the previous week, the month change is a 7.45% rise, over the last year CRISPR THERAPEUTIC has showed a −28.42% decrease.
We've gathered analysts' opinions on CRISPR THERAPEUTIC future price: according to them, 1CG price has a max estimate of 176.46 CHF and a min estimate of 26.60 CHF. Watch 1CG chart and read a more detailed CRISPR THERAPEUTIC stock forecast: see what analysts think of CRISPR THERAPEUTIC and suggest that you do with its stocks.
1CG stock is 2.26% volatile and has beta coefficient of 1.52. Track CRISPR THERAPEUTIC stock price on the chart and check out the list of the most volatile stocks — is CRISPR THERAPEUTIC there?
Today CRISPR THERAPEUTIC has the market capitalization of 4.17 B, it has decreased by −2.19% over the last week.
Yes, you can track CRISPR THERAPEUTIC financials in yearly and quarterly reports right on TradingView.
CRISPR THERAPEUTIC is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
1CG earnings for the last quarter are −0.86 CHF per share, whereas the estimation was −1.17 CHF resulting in a 27.06% surprise. The estimated earnings for the next quarter are −1.08 CHF per share. See more details about CRISPR THERAPEUTIC earnings.
CRISPR THERAPEUTIC revenue for the last quarter amounts to 510.15 K CHF, despite the estimated figure of 5.57 M CHF. In the next quarter, revenue is expected to reach 6.96 M CHF.
1CG net income for the last quarter is −72.83 M CHF, while the quarter before that showed −113.65 M CHF of net income which accounts for 35.92% change. Track more CRISPR THERAPEUTIC financial stats to get the full picture.
No, 1CG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 3, 2024, the company has 407.00 employees. See our rating of the largest employees — is CRISPR THERAPEUTIC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CRISPR THERAPEUTIC EBITDA is −265.26 M CHF, and current EBITDA margin is −54.61%. See more stats in CRISPR THERAPEUTIC financial statements.
Like other stocks, 1CG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CRISPR THERAPEUTIC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CRISPR THERAPEUTIC technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CRISPR THERAPEUTIC stock shows the sell signal. See more of CRISPR THERAPEUTIC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.